您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 德国药房
产地国家: 德国
所属类别: 影响血液及造血系统药物->抗血小板凝聚药
处方药:处方药
包装规格: 5毫克/片 28片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
礼来
生产厂家英文名:
Lilly Deutschland GmbH
该药品相关信息网址1:
http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=1037
该药品相关信息网址2:
http://www.medicines.org.uk/emc/document.aspx?documentid=21504&docType=SPC
原产地英文商品名:
EFIENT 5mg/tab 28tabs/box
原产地英文药品名:
PRASUGREL HYDROCHLORIDE
中文参考商品译名:
EFIENT 5毫克/片 28片/盒
中文参考药品译名:
盐酸普拉格雷
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
oral antiplatelet agent
临床试验期:
完成
中文适应病症参考翻译1:
口服抗血小板药物
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201061119565531.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Efient处方资料(仅供参考)

    欧盟批准第一制药-三共公司与礼来公司联合开发的普拉格雷薄膜包衣片(prasugrel,Efient)上市,用于预防经皮冠状动脉介入治疗(PCI)急性冠状动脉综合征(ACS)患者的动脉粥样栓塞发生。本品剂量规格:普拉格雷5 mg/片、10 mg/片。

    此次欧洲批准本品对医生和患者是个好消息,这是由于欧盟每年死于心脏病发作的患者多达70万例以上。ACS系可能威胁生命的严重疾病,本品可作为进行PCI的ACS患者重要的新治疗方法。

    普拉格雷通过抑制血小板表面特异受体(P2Y12二磷酸腺苷),防止血小板凝聚(造成动脉阻塞、导致心脏病发作)来发挥作用。

    一项大规模Ⅲ期临床研究显示,普拉格雷减少进行PCI的ACS患者重大心血管疾病的危险(按心血管疾病死亡、非致死性心脏病发作或非致死性休克的综合评判)优于氯吡格雷(clopidogrel,Plavix/Iscover)。

Drug Name: Efient (prasugrel)

Company: Eli Lilly
Approval Status: Approved July 2009
Treatment Area: prevention of thrombotic cardiovascular complications in acute coronary syndromes

General Information
Efient (prasugrel) works by reducing the tendency of platelets, the blood particles responsible for clotting, from sticking or clumping together. Prasugrel blocks a specific receptor on the platelet surface, P2Y12 adenosine diphosphate (ADP), and prevents platelets from clumping, which can result in clogged arteries and may lead to heart attack.

Efient is specifically indicated to reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows:
Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI)
Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.

Efient is supplied as a 5 mg or 10 mg tablet for oral administration. The recommended initial dose of the drug is as a single 60 mg oral loading dose which may be continued at 10 mg orally once daily. Patients taking Effient should also take aspirin (75 mg to 325 mg) daily.
Dosing in Low Weight Patients Patients weighing < 60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10 mg once daily maintenance dose. Consider lowering the maintenance dose to 5 mg in this population.

Clinical Results
FDA Approval
The FDA approval of Efient was based on the results of TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel). This multicenter, international, randomized, double-blind, parallel-group study enrolled 13,608 subjects with ACS (UA, NSTEMI, or STEMI) who were to be managed with PCI. The subjects were randomized to receive Effient (60 mg loading dose followed by 10 mg once daily) or clopidogrel (300 mg loading dose followed by 75 mg once daily), with administration and follow-up for a minimum of 6 months (actual median 14.5 months). Patients also received aspirin (75 mg to 325 mg once daily). The primary outcome measure was the composite of cardiovascular death, nonfatal MI, or nonfatal stroke in the UA/NSTEMI population. Success in this group allowed analysis of the same endpoint in the overall ACS and STEMI populations. Efient produced a statistically significant reduction in this primary endpoint of 19% when compared to Plavix (p=0.0004). This was observed as early as three days into treatment. In a subgroup of subjects with diabetes, prasugrel reduced each of the endpoints by 21% in subjects with STEMI (p=0.02) and 18% in subjects with unstable angina (p=0.002), compared to Plavix. In addition, prasugrel resulted in a 34% decline in urgent target vessel revascularization (p<0.001) and a 42% reduction in heart attack with subsequent death from cardiovascular causes (p=0.02). Prasugrel treated subjects also had a statistically significant increase in non-CABG (coronary artery bypass grafting) major bleeding compared to Plavix-treated subjects (2.4% vs. 1.8%, p=0.03). Fatal bleeding was statistically more frequent among prasugrel-treated than clopidogrel-treated subjects (0.4% vs. 0.1%, p=0.002). Overall, prasugrel showed a higher clinical benefit over Plavix, with a significant 13% reduction in overall events (12.2 vs. 13.9, p=0.004).

Ongoing Study Commitments
•Eli Lilly has agreed to conduct an open-label trial of ex vivo reversal of platelet inhibition by exogenous platelets as a function of time and plasma level of prasugrel active metabolite in 28 normal volunteers administered a single 60-mg loading dose of prasugrel plus aspirin 325 mg.
Final Protocol Submission: 09/2009
Trial Completion Date: 08/2011
Final Report Submission: 09/2011
•Eli Lilly has agreed to gather baseline cancer history and cancer adverse event data from the ongoing trial TRILOGY, a 10,300-subject trial being conducted in patients with acute coronary syndrome who are being managed medically (without coronary revascularization).
Protocol Submission: 06/2008
Trial Completion Date: 12/2012
Final Report Submission: 01/2013
•Eli Lilly has agreed to perform a clinical trial in the fasting and fed state, to compare the pharmacokinetics of single 60-mg doses of the marketed and new prasugrel formulations with respect to concentrations of the prasugrel active metabolite and effects on platelet inhibition.
Trial Completion Date: 08/2009
Final Report Submission: 12/2009
•perform, in the presence and absence of a proton pump inhibitor, a clinical trial to compare the pharmacodynamics of single 60-mg doses of the marketed and new prasugrel formulations with respect to concentrations of the prasugrel active metabolite and effects on platelet inhibition.
Final Report Submission: 12/2009
•Eli Lilly has commited to the collection of samples at baseline for genotyping CYP450 enzymes in TRILOGY subjects, to allow a comparison of effectiveness and bleeding in prasugrel and clopidogrel subgroups by metabolizer status.
Trial Completion Date: 12/2012
Final Report Submission: 01/2013

Side Effects
Adverse events associated with the use of Efient may include, but are not limited to, the following:
•TIMI major or minor bleeding
•Hypertension
•Hypercholesterolemia/Hyperlipidemia
•Headache
•Back Pain
Dyspnea
•Nausea
•Dizziness

Mechanism of Action
Efient contains prasugrel, a thienopyridine class inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP receptor. Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.

Literature References
Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD; TRITON-TIMI 38 Investigators Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal 2009 Jul;30(14):1753-63

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009 Feb 28;373(9665):723-31

Scott DM, Norwood RM, Parra D P2Y(12) inhibitors in cardiovascular disease: focus on prasugrel.The Annals of Pharmacotherapy 2009 Jan;43(1):64-76.

Braun OO, Johnell M, Varenhorst C, James S, Brandt JT, Jakubowski JA, Winters KJ, Wallentin L, Erlinge D, Siegbahn A Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thrombosis and Haemostasis 2008 Oct;100(4):626-33

Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007 Dec 18;116(25):2923-32

Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T, Freestone S, Winters KJ A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. British Journal of Clinical Pharmacology 2007 Apr;63(4):421-30

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005 Jun 28;111(25):3366-73

Additional Information
For additional information regarding Efient or thrombotic cardiovascular events in patients with acute coronary syndrome managed with PCI, please visit the Efient web page.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201061119565531.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

于2011-04-21更新

更新日期: 2013-08-08
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com